Jim Cramer Says Eli Lilly CEO Is a “Terrific Steward of His Shareholders’ Capital”
Key takeaways
- Cramer noted that the company’s GLP-1 franchise is the best, as he said:
- CEO David Ricks is a terrific steward of his shareholders’ capital.
- The big problem with GLP-1s is that they make you lose both muscle and fat.
Jim Cramer Says Eli Lilly CEO Is a “Terrific Steward of His Shareholders’ Capital” Syeda Seirut Javed Sat, June 6, 2026 at 10:06 PM GMT+7 3 min read LLY Eli Lilly and Company (NYSE:LLY) was among the stocks on which Jim Cramer gave his opinion, as he warned that increased AI-related spending might cause near-term headwind for stocks. Cramer noted that the company’s GLP-1 franchise is the best, as he said:
CEO David Ricks is a terrific steward of his shareholders’ capital. Still, at the end of the day, the thesis here boiled down to the simple fact that Lilly’s got the best GLP-1 franchise… In the last two weeks, though, we’ve gotten some major bullish catalysts from Eli Lilly… First, on May 21st, Lilly reported new data from a Phase 3 trial… The data from this trial showed Retatrutide is much more effective for weight loss than the GLP-1s that we currently have… But an unspoken part of the story, and this is, you know, I gotta be really careful here because they’ve not been approved for this, right, it’s about muscle atrophy.
The big problem with GLP-1s is that they make you lose both muscle and fat. There’s been a lot of speculation that Retatrutide will help you lose more fat and less muscle… But that’s why so many people are taking it in the gray market… It’s telling that there’s so much demand for something that isn’t even out yet. It could be the biggest drug of all time. You heard me, biggest drug of all time. The key is that, at least so far, no one else has a weight loss drug in the pipeline that’s in the same league as what Lilly’s working on.